Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

PerkinElmer divests three business units in $2.45 billion deal

Stock Markets Aug 01, 2022 05:20PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: A sign marks a PerkinElmer facility in Boston, Massachusetts, U.S., May 15, 2020. REUTERS/Brian Snyder/File Photo

By David Carnevali and Leroy Leo

(Reuters) -PerkinElmer Inc on Monday agreed to sell three of its businesses to private equity firm New Mountain Capital for up to $2.45 billion in cash, as it looks to focus on its life sciences and diagnostics businesses under a new name.

The latest deal is among a wave of recent corporate carve-outs and spinoffs. Last week, 3M Co announced it would spin off its healthcare unit, while Labcorp agreed to separate its clinical development business.

Direct lenders led by Owl Rock Capital (NYSE:ORCC) Corp helped finance the deal entirely, amid a slowdown in the business of acquisition financing as both traditional and direct lenders have pulled back from lending on leveraged buyouts in recent weeks.

Proceeds from the divestiture will be used to invest in growth in the life sciences and diagnostics segments and to fund future acquisitions, PerkinElmer (NYSE:PKI) said. Diagnostics will generate around 60% of the company’s 2022 estimated revenue of $3.3 billion, while life sciences will account for the remainder.

The sale marked the conclusion of a strategic review where other options, including a spinoff of the units, were also considered, according to a source familiar with the matter.

The sale process included both strategic and private equity suitors, the source said, requesting anonymity as these discussions were confidential.

The price tag of the three units - applied, food, and enterprise services - implies a valuation of about 14 to 16 times the company's 2022 estimated EBITDA (earnings before interest taxes depreciation and amortization), the source said.

Shares of PerkinElmer closed up 5% at $160.87 on Monday. The transaction is expected to close in the first quarter of 2023, subject to regulatory approvals.

PerkinElmer will receive $2.3 billion when the deal closes, while the remaining $150 million will be paid to the company later, contingent on the businesses reaching certain return milestones under New Mountain's ownership.

The divested businesses will continue to use the PerkinElmer brand, while the life sciences and diagnostics businesses that remain will be run by the existing management under a new name and stock ticker that will be announced later, PerkinElmer said.

"The divestiture on (the) surface improves the growth profile of the company," Evercore analyst Vijay Kumar said in a note.

Goldman Sachs (NYSE:GS) advised PerkinElmer on the deal, while Jefferies advised New Mountain Capital.

PerkinElmer divests three business units in $2.45 billion deal

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email